Privately held Hemoshear Therapeutics LLC signaled its intention to compete both with small peers and big biopharma in the race to develop therapies for liver diseases, especially nonalcoholic steatohepatitis (NASH), by luring Takeda Pharmaceutical Co. Ltd. to a funded three-year discovery and development pact.